Growth and puberty in thalassemia major

Journal of Pediatric Endocrinology and Metabolism

Volumn 16, Issue SUPPL. 2, 2003, Pages 259-266

  Raiola, Giuseppe ^a,g   Galati, M C ^a   De Sanctis, V ^b   Nicoletti, M Caruso ^c   Pintor, C ^d   De Simone, M ^e   Arcuri, V M ^a   Anastasi, S ^f  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b S ANNA HOSPITAL   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

^f GARIBALDI HOSPITAL   (Italy)

^g Garibaldi Hospital ^*  (Italy)

Author keywords

Chelation therapy; Genotype; Growth failure; Hypogonasdism; MRI; Replacement therapy; Thalassemia major; Transfusional therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CHORIONIC GONADOTROPIN; CYCLOPHOSPHAMIDE; DEFEROXAMINE; ESTROGEN; ETHINYLESTRADIOL; GONADORELIN; GONADOTROPIN; GROWTH HORMONE; HUMAN MENOPAUSAL GONADOTROPIN; INSULIN; IRON CHELATING AGENT; RECOMBINANT GROWTH FACTOR; SEX HORMONE; SOMATOMEDIN; TESTOSTERONE ENANTATE;

ADOLESCENT; ARTICLE; BLOOD TRANSFUSION; BONE DYSPLASIA; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL PROTOCOL; ENDOCRINE DISEASE; FOLLOW UP; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOGONADISM; IRON OVERLOAD; LIFE EXPECTANCY; LIVER DISEASE; MAJOR CLINICAL STUDY; PUBERTY; RISK FACTOR; SEXUAL DEVELOPMENT; SHORT STATURE; SIDEROSIS; SPERMATOGENESIS; THALASSEMIA MAJOR; BETA THALASSEMIA; BODY HEIGHT; CHELATION THERAPY; GROWTH; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

BETA-THALASSEMIA; BODY HEIGHT; BONE MARROW TRANSPLANTATION; CHELATION THERAPY; GROWTH; HUMANS; HYPOGONADISM; PUBERTY;

EID: 0141960953     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Fosburg MT, Nathan DG. Treatment of Cooley's anemia. Blood 1990; 76: 435-444.
2. Hoffbrand AV, Wonke B. Iron chelation therapy. J Intern Med 1997; 242: 37-41.
3. Britton RS, Ramm GA, Olynyk J, Singh R, O'Neil R, Bacon BR. Pathophysiology of iron toxicity. Adv Exp Med Biol 1994; 356: 239-253.
4. Brittenham GM, Griffith PM, Nienhuis AW. Efficacy of desferoxamine in preventing complications of iron overload in patients with thalassaemia major. N Engl J Med 1994; 331: 567-573.
5. Olivieri NF. Orally active oral chelators in the treatment of iron overload. Curr Opin Haematol 1996; 3: 125-130.
6. Oliveri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassaemia. Blood 1997; 89: 739-761.
7. Cartwright GE, Edwards CQ, Kravitz K, Skolnick M, Amos DB, Johnson A, Buskjaer L. Hereditary hemochromatosis. Phenotypic expression of the disease. N Engl J Med 1979; 301: 175-179.
8. Cohen A, Martin M, Schwartz E. Depletion of excessive liver iron stores with desferoxamine. Br J Haematol 1984; 58: 369-373.
9. Flynn DM, Hoffbrand AV, Politis D. Subcutaneous desferrioxamine: the effect of three years treatment on liver iron, serum ferritin and comments for echocardiography. Birth Defects 1982; 18; 347-353.
10. De Sanctis V, Urso L. L'accrescimento staturale nella thalassemia. Min Pediatr 1997; 4: 121-128.
11. De Sanctis V, Caruso Nicoletti M, Pintor C, Raiola G. Guidelines for the diagnosis and treatment of endocrinopathies in thalassaemia. Riv Ital Pediatr (IJP) 1999; 25: 1132-1137.
12. Caruso Nicoletti M, De Sanctis V, Anastasi S, Cavagnini F, Cavallo L, Cilia A, Cisternino M, De Luca F, De Simone M, Di Gregorio F, Einaudi S, Galati MC, Gallisai D, Gerardi C, Malizia R, Mangiagli A, Meo A, Pasquino AM, Pintor C, Ponzi G, Quarta G, Romondia A, Ruggiero L, Saviano A, Sacco M, Stefano I. Guidelines for the auxological follow-up of thalassaemic patients. Riv Ital Pediatr (IJP) 1997; 23: 305-307.
13. Costin G, Kogut MD, Hyman CB, Ortaga JA. Endocrine abnormalities in thalassaemia major. Am J Dis Child 1979; 133: 497-502.
14. Karagiorga-Lagana M, Papadakou-Lagoyanni S, Pantelakis S, Lapatasanis P, Karaklis A. Body growth in Cooley's anemia in relation to hemoglobin and ferritin levels. Iatriki 1980; 38: 38-36.
15. Langer J, Girot R, Crosnier H, Postel-Vinay MC, Rappaport R. GH response to GH-RH in children with thalassaemia major before puberty: a possible age related effect. J Clin Endocrinol Metab 1989; 69: 453-456.
16. Tolis G, Politis C, Kontopoulou I, Poulatzas N, Rigas G, Saridakis C, Athanasiou V, Mortoglou-Malachtari S, Ling N. Pituitary somatotropic and corticotropic function in patients with β-thalassaemia on iron chelation therapy. Birth Defects 1988; 23: 449-452.
17. Chatterjee R, Katz M, Cox T, Bantock H. Evaluation of growth hormone in thalassaemic boys with failed puberty: spontaneous versus provocative test. Eur J Pediatr 1993; 152: 721-726.
18. Roth C, Pekrum A, Batz M, Jarry H, Eber S, Lakomek M, Shroter W. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr 1997; 156: 777-783.
19. Shehaded N, Hazani A, Rudolf MCJ, Peleg I, Benderly A, Hochberg Z. Neurosecretory dysfunction of growth hormone secretion in thalassaemia major. Acta Paediatr Scand 1990; 79: 790-795.
20. Saenger P, Schwaartz E, Makenson AL, Graziano JH, Levine LS, New MI, Hilgartner MW. Depressed serum somatomedin activity in β-thalassaemia major. J Pediatr 1980; 96: 214-218.
21. Werther GA, Mathews RN, Burger HG, Herington AC. Lack of response of non-suppressible insulin-like activity in thalassaemia major. J Clin Endocrinol Metab 1981; 53: 806-809.
22. De Sanctis V, Urso L, Galati MC, Mangiagli A, Massolo L, Ponzi G, Ruggiero L, Sacco M, Cavallini AR, Rigolin F. Growth hormone (GH) treatment in thalassaemic patients with short stature, GH insufficiency and different severity of iron overload. Bone Marrow Transplant 1997; 19 (Suppl 2): 32-33.
23. Katzos G, Papakostantinou-Athanasiadou E, Athanasiou-Metaxa M, Harsoulis F. Growth hormone treatment in short children with β-thalassaemia major. J Pediatr Endocrinol Metab 2000; 13: 163-170.
24. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassemia major. Clin Endocrinol 1995; 42: 581-586.
25. Cohen AR. Iron overload in the pediatric patient. In: Oski FA, ed. Haematology/Oncology Clinics of North America. Philadelphia, PA: Saunders, 1987; 521-544.
26. Berkovitch M, Bistritzer T, Milone SD, Perlman K, Kucharczyk W, Koren G, Olivieri NF. Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function. J Pediatr Endocrinol Metab 2000; 13: 179-184.
27. Jensen CE, Tuck SM, Old J, Morris RW, Yardumian A, De Sanctis V, Hoffbrand AV, Wonke B. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with β-thalassaemia. Eur J Haematol 1997; 59: 76-81.
28. Galati MC, Puzzonia P, Consarino C, Grimaldi S, Morgione S, Porcelli D, Raiola G, Santilli E, Tancrè D, Magro S. Sexual maturation in twelve females with homozygous beta thalassaemia (abstract . International Conference on Endocrine Disorders in Thalassemia, May 1992, Cosenza, Italy.
29. Annoussakis CH, Allexiou D, Abatzis D, Bechrakis G. Endocrinological investigation of pituitary gonadal axis in thalassemia major. Acta Paediatr Scand 1977; 66: 49-51.
30. Bals-Pratsch M, Langer K, Place VA, Nieschlag E. Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol (Copenh) 1988; 118: 7-13.
31. Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajarain L, Sanders SW, Mazer NA. Long term efficacy and safety of permeation enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 1997; 47: 727-737.
32. McClellan KJ, Goa KL. Transdermal testosterone. Drugs 1998; 55: 253-258.
33. De Sanctis V, Vullo C, Urso L, Rigolin F, Cavallini A, Caramelli K, Daugherty C, Mazer N. Clinical experience using the Androderm® testosterone transdermal system in hypogonadal adolescents and young men with β-thalassaemia major. J Pediatr Endocrinol Metab 1998; 11 (Suppl 3): 891-900
34. Cisternino M, Magni Manzoni S, Coslovich EE, Autelli M. Hormonal replacement therapy with HCG and HU-FSH in thalassaemic patients affected by hypogonadotropic hypogonadism. J Pediatr Endocrinol Metab 1998; 11 (Suppl 3): 885-890.
35. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin N Am 1994; 23: 857-875.
36. Whitcomb RW, Crowley WF Jr. Clinical Review 4: Diagnosis and treatment of isolated gonadotropin-releasing hormone deficiency in men. J Clin Endocrinol Metab 1990; 70: 3-7.
37. Chatterjee R, Katz M, Wonke B, Hoffbrand AV, Politis D. Induction of puberty in beta thalassaemia major. Birth Defects 1987; 23: 453-458.
38. Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, Erten S, Tuck S, Agnew JE, Raja K, Davies K, Hoffbrand AV. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab 1998; 11 (Suppl 3): 795-801.
39. Vannasaeg S, Fucharoen S, Pootrakul P, Ployburr S, Yansukon P. Pituitary function in thalassemic patients and the effect of chelation therapy. Acta Endocrinol 1991; 124: 23-30.
40. Oerter KE, Kamp GA, Munson PJ, Nienhuis AW, Cassarola FG, Manasco PK. Multiple hormone deficiencies in children with hemochromatosis. J Clin Endocrinol Metab 1993; 76: 357-361.
41. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freeman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in beta thalassaemia major. N Engl J Med 1990; 323: 713-719.
42. Di Bartolomeo P, Di Girolamo G, Angrilli F, Bavaro P, Olioso P, Papalinetti G, Accorsi P, Quaglietta AM. Treatment of thalassemia by allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12 (Suppl 1): 37-41.
43. Lucarelli G, Galimberti M, Polchi, Angelici E, Baronciani D, Giardini C, Politi P, Durazzi SM, Muretto P, Alberini F. Bone marrow transplantation in patients with thalassaemia. N Engl J Med 1990; 322: 417-421.
44. Borgna-Pignatti C. Bone marrow transplantation for the hemoglobinopathies. In: Trealeven J, Barrett J, Gale RP, eds. Bone Marrow Transplantation in Practice. London: Churchill-Livingstone, 1992, 151-159.
45. De Simone M, Verrotti A, Iughetti L, Palumbo M, Di Bartolomeo P, Olioso P, Rosato T. Final height of thalassaemic patients who underwent bone marrow transplantation during childhood. Bone Marrow Transplant; 2001; 28: 201-205.
46. Benker G, Schafer U, Hermanns U, Mahmoud MK, Olbricht T, Schulte HM, Windeck R, Reinwein D. Allogenic bone marrow transplantation in adults: endocrine sequelae after 1-6 years. Acta Endocrinol (Copenh) 1989; 120: 37-42.
47. Sklar CA, Kim TH, Williamson JF, Ramsay NK. ovarian function after successful bone marrow transplantation in postmenarcheal females. Med Pediatr Oncol 1983; 11: 361-364.
48. Sanders JE, Buckner CD, Amos D, Levy W, Appelbaum FR, Doney K, Storb R, Sullivan KM, Witherspoon RP, Thomas ED. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 1988; 6: 813-818.
49. De Sanctis V, Galimberti M, Lucarelli G, Angelucci E, Ughi M, Baronciani D, Polchi P, Giardini C, Bagni B, Vullo C. Pubertal development in thalassaemic patients after allogenic bone marrow transplantation. Eur J Pediatr 1993; 152: 993-997.